NEW YORK, June 13, 2013 /PRNewswire/ — IntelliCell BioSciences, Inc. (“Company”) (SVFC) announces that it has been notified by the US Patent office that its patent for stem cell extraction technology has been published. IntelliCell’s proprietary patented method for deriving blood vessel originated vascular cells from adipose (fat) tissue by use of ultrasonic cavitation has been made official. This technology involves an innovative mechanical method for the separation of stromal vascular fraction cells from adipose (fat) tissue, without the use of enzymes. Vascular cells derived by IntelliCell’s proprietary method are potentially useful in bringing the promise of regenerative medicine to many therapeutic and aesthetic procedures. Investors can access the published patent at the US Patent website by entering the patent # 8,440,440. Link to patent website: http://patft.uspto.gov/netahtml/PTO/srchnum.htm
IntelliCell’s Chairman and CEO, Dr. Steven Victor, stated “Our Company is very pleased to announce today that with the publishing of our patent, our technology is now protected and we expect our international patent publication in a short time.”
About IntelliCell BioSciences, Inc.
IntelliCell BioSciences is a Regenerative Medicine company developing novel technologies that address the regenerative, curative and preventative conditions of disease states with high unmet clinical needs. The Company has several patent-pending applications including the patent that was recently published, an industry unique method of obtaining autologous stromal vascular fraction cells (SVF) cells from the vasculature surrounding adipose tissue containing adult stem cells and a robust population of regenerative healing cells. The Company is also pioneering the development of autologous and allogeneic cells from living and non-living tissue donors for research purposes. IntelliCell is planning a series of in-human clinical studies with top tier universities for the treatment of osteoarthritis, multiple sclerosis, lower limb ischemic wounds, and gum regeneration in the oral cavity as well as medical aesthetics. The Company has developed a first in class cGTP cellular processing facility in New York City, purpose built and designed to be fully integrated into an ambulatory surgery center.